Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
Unknown unknown
|
colorectal cancer
|
not applicable |
Bleomycin + CBP501
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, treatment with the combination of Blenoxane (bleomycin) and CBP501 resulted in enhanced tumor growth inhibition in cell line xenograft models of colorectal cancer, compared to either agent alone (PMID: 17237275).
|
17237275
|
Unknown unknown
|
pancreatic cancer
|
not applicable |
Bleomycin + CBP501
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of Blenoxane (bleomycin) and CBP501 resulted in increased cell death compared to Blenoxane (bleomycin) alone in a human pancreatic cancer cell line in culture (PMID: 17237275).
|
17237275
|